Publication | Closed Access

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

Hematological MalignancyOncologyMixed-phenotype Acute LeukemiaHematologyClinical TrialsHaematological RelapseMyeloid NeoplasiaAcute Myeloid LeukaemiaPharmacotherapyPhase 2MedicineRadiation OncologyHealth Sciences